Advertisement

Pneumo News

, Volume 10, Issue 6, pp 31–38 | Cite as

Interstitielle Lungenerkrankung

Taugt bei akut exazerbierter idiopathischer Lungenfibrose der Kortisonstoß noch?

  • Markus Polke
  • Michael Kreuter
cme fortbildung
  • 55 Downloads

Zusammenfassung

Die akute Exazerbation einer idiopathischen Lungenfibrose (AE-IPF) ist definiert als akute respiratorische Verschlechterung bei IPF-Patienten. Für die Diagnosestellung müssen bestimmte Kriterien erfüllt sein. Ursache und Pathophysiologie des Krankheitsbildes sind noch nicht genau verstanden. Die Prognose einer AE-IPF ist sehr schlecht und konsertierte Therapiemaßnahmen sind noch nicht etabliert, wenn auch eine hochdosierte Steroidtherapie in der Klinik regelhaft angewandt wird.

Literatur

  1. 1.
    Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824CrossRefGoogle Scholar
  2. 2.
    Ley B, Collard HR, King TE, Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–40CrossRefGoogle Scholar
  3. 3.
    Kreuter M, Ehlers-Tenenbaum S, Palmowski K et al. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PloS one. 2016;11(3):e0151425CrossRefGoogle Scholar
  4. 4.
    Kreuter M, Swigris J, Pittrow D et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practicinsights-IPF registry. Respir Res. 2017;18(1):139CrossRefGoogle Scholar
  5. 5.
    Behr J, Gunther A, Bonella F et al. [German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017]. Pneumologie. 2017;71(7):474CrossRefGoogle Scholar
  6. 6.
    Kim DS, Park JH, Park BK et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J. 2006;27(1):143–50CrossRefGoogle Scholar
  7. 7.
    Simon-Blancal V, Freynet O, Nunes H et al. Acute exacerbation of idiopathic pulmonary fibrosis: outcome and prognostic factors. Respiration. 2012;83(1):28–35CrossRefGoogle Scholar
  8. 8.
    Collard HR, Ryerson CJ, Corte TJ et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265–75CrossRefGoogle Scholar
  9. 9.
    Molyneaux PL, Cox MJ, Wells AU et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):29CrossRefGoogle Scholar
  10. 10.
    Petrosyan F, Culver DA, Reddy AJ. Role of bronchoalveolar lavage in the diagnosis of acute exacerbations of idiopathic pulmonary fibrosis: a retrospective study. BMC Pulm Med. 2015;15:70CrossRefGoogle Scholar
  11. 11.
    Collard HR, Yow E, Richeldi L et al. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res. 2013;14:73CrossRefGoogle Scholar
  12. 12.
    Lee JS, Song JW, Wolters PJ et al. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):352–8CrossRefGoogle Scholar
  13. 13.
    Lee JS, Collard HR, Anstrom KJ et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369–76CrossRefGoogle Scholar
  14. 14.
    Johannson KA, Vittinghoff E, Lee K et al. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur Respir J. 2014;43(4):1124–31CrossRefGoogle Scholar
  15. 15.
    Kuhn C, 3rd, Boldt J, King TE, Jr. et al. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis. 1989;140(6):1693–703CrossRefGoogle Scholar
  16. 16.
    Konishi K, Gibson KF, Lindell KO et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;180(2):167–75CrossRefGoogle Scholar
  17. 17.
    Collard HR, Calfee CS, Wolters PJ et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(1):L3–7CrossRefGoogle Scholar
  18. 18.
    Moeller A, Gilpin SE, Ask K et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. 2009;179(7):588–94Google Scholar
  19. 19.
    Maharaj S, Shimbori C, Kolb M. Fibrocytes in pulmonary fibrosis: a brief synopsis. Eur Respir Rev. 2013;22(130):552–7CrossRefGoogle Scholar
  20. 20.
    Gunther A, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev. 2012;21(124):152–60CrossRefGoogle Scholar
  21. 21.
    Qiu M, Chen Y, Ye Q. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Clin Respir J. 2018;12(3):1084–92CrossRefGoogle Scholar
  22. 22.
    Kondoh Y, Taniguchi H, Katsuta T et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2010;27(2):103–10PubMedGoogle Scholar
  23. 23.
    Kolek V, Vasakova M, Sterclova M et al. [Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis]. Klin Onkol. 2017;30(4):303–6CrossRefGoogle Scholar
  24. 24.
    Sakamoto K, Taniguchi H, Kondoh Y et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med. 2012;106(3):436–42CrossRefGoogle Scholar
  25. 25.
    Suzuki H, Sekine Y, Yoshida S et al. Risk of acute exacerbation of interstitial pneumonia after pulmonary resection for lung cancer in patients with idiopathic pulmonary fibrosis based on preoperative high-resolution computed tomography. Surg Today. 2011;41(7):914–21CrossRefGoogle Scholar
  26. 26.
    Ghatol A, Ruhl AP, Danoff SK. Exacerbations in idiopathic pulmonary fibrosis triggered by pulmonary and nonpulmonary surgery: a case series and comprehensive review of the literature. Lung. 2012;190(4):373–80CrossRefGoogle Scholar
  27. 27.
    Papiris SA, Kagouridis K, Kolilekas L et al. Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach. BMC Pulm Med. 2015;15:162CrossRefGoogle Scholar
  28. 28.
    Kreuter et al. A global perspective on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF): results from an international survey. ERS 2018 International Congress, Vortrag OA542, 16.9.2018Google Scholar
  29. 29.
    Donahoe M, Valentine VG, Chien N et al. Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis. PloS one. 2015;10(6):e0127771CrossRefGoogle Scholar
  30. 30.
    Sakamoto S, Homma S, Miyamoto A et al. Cyclosporin A in the treatment of acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2010;49(2):109–15CrossRefGoogle Scholar
  31. 31.
    Horita N, Akahane M, Okada Y et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med. 2011;50(3):189–95CrossRefGoogle Scholar
  32. 32.
    Abe S, Hayashi H, Seo Y et al. Reduction in serum high mobility group box-1 level by polymyxin B-immobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif. 2011;32(4):310–6CrossRefGoogle Scholar
  33. 33.
    Isshiki T, Sakamoto S, Kinoshita A et al. Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis: a retrospective study. Respiration. 2015;89(3):201–7CrossRefGoogle Scholar
  34. 34.
    Kawamura K, Ichikado K, Yasuda Y et al. Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study. BMC Pulm Med. 2017;17(1):94CrossRefGoogle Scholar
  35. 35.
    Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014;14:139CrossRefGoogle Scholar
  36. 36.
    Dotan Y, Vaidy A, Shapiro W et al. Effect of Acute Exacerbation of Idiopathic Pulmonary Fibrosis on Lung Transplantation Outcome. Chest. 2018. https://doi.org/10.1016/j.chest.2018.06.027CrossRefGoogle Scholar
  37. 37.
    Rush B, Wiskar K, Berger L, Griesdale D. The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: A nationwide retrospective cohort analysis. Respir Med. 2016;111:72–6CrossRefGoogle Scholar
  38. 38.
    Johannson K, Collard HR. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal. Curr Respir Care Rep. 2013;2(4). https://doi.org/10.1007/s13665-013-0065-xCrossRefGoogle Scholar
  39. 39.
    Lee JS, Ryu JH, Elicker BM et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390–4CrossRefGoogle Scholar
  40. 40.
    Kreuter M, Wuyts W, Renzoni E et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4(5):381–9CrossRefGoogle Scholar
  41. 41.
    Meyer KC, Raghu G, Baughman RP et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–14CrossRefGoogle Scholar
  42. 42.
    Behr J, Gunther A, Bonella F, et al. [German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017]. Pneumologie. 2017;71(7):460–74CrossRefGoogle Scholar
  43. 43.
    Richeldi L, Costabel U, Selman M et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079–87CrossRefGoogle Scholar
  44. 44.
    Richeldi L, du Bois RM, Raghu G et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82CrossRefGoogle Scholar
  45. 45.
    Richeldi L, Cottin V, du Bois RM et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med. 2016;113:74–9CrossRefGoogle Scholar
  46. 46.
    Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040–7CrossRefGoogle Scholar
  47. 47.
    Ley B, Swigris J, Day BM et al. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017;196(6):756–61CrossRefGoogle Scholar
  48. 48.
    Iwata T, Yoshida S, Nagato K et al. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis. Surg Today. 2015;45(10):1263–70CrossRefGoogle Scholar
  49. 49.
    Taniguchi H, Ebina M, Kondoh Y et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–9CrossRefGoogle Scholar
  50. 50.
    Sekine Y, Ko E. [The influence of intraoperative oxygen inhalation on patients with idiopathic pulmonary fibrosis]. Masui. 2011;60(3):307–13PubMedGoogle Scholar
  51. 51.
    Mizuno Y, Iwata H, Shirahashi K et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41(6):e161–5CrossRefGoogle Scholar
  52. 52.
    Polke et al. Diagnosis and therapy of acute exacerbations of acute pulmonary fibrosis (AE-IPF) in Germany. ERS 2018 International Congress, Vortrag PA2903, 17.9.2018Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Zentrum für interstitielle und seltene Lungenerkrankungen, Pneumologie, ThoraxklinikUniversitätsklinkum HeidelbergHeidelbergDeutschland

Personalised recommendations